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Abstract
A large proportion of cervical cancer patients have a lower socioeconomic background and barriers to clinical
trial participation. We hypothesized that patients participating in a clinical trial would have better outcomes
compared to those not enrolled in a trial. This was a retrospective cohort study of women treated for recurrent
cervical cancer on versus off clinical trial. We found that the progression free and overall survival between
women treated with chemotherapy on or off trial for cervical cancer survival is similar.
Introduction: A large proportion of patients with cervical cancer have a lower socioeconomic background with
inherent barriers to clinical trial participation. The present authors hypothesized that patients participating in a clinical
trial would have better outcomes compared with those not enrolled in a trial. The objective was to review the clinical
outcomes of women with recurrent cervical cancer treated on a clinical trial versus those treated off trial. Patients and
Methods: This was a retrospective cohort study of women treated for recurrent cervical cancer on versus off clinical
trial between 1998 and 2010. Women participating in Gynecologic Oncology Group clinical trials for recurrent cervical
cancer were identiﬁed and matched 1:1 with women treated off trial based on age within 10 years, ethnicity, stage at
initial diagnosis, histology, primary treatment, and baseline renal function. Results: A total of 60 women with recurrent
cervical cancer were identiﬁed; 30 were treated for their recurrence on a clinical trial and were matched to 30 treated
off trial. The median number of salvage regimens was 1.0 for the trial group (range, 1-5) and 1.5 for the off-trial group
(range, 1-5) (P ¼ .74). There was no signiﬁcant difference in the number of cycles of chemotherapy completed on
versus off trial (7.5 vs. 5.9; P ¼ .44). There was also no signiﬁcant difference in progression-free and overall survival
from time of recurrence on trial and off trial (4.2 vs. 3.1 months [P ¼ .75] and 15.0 vs. 13.8 months [P ¼ .64],
respectively). Conclusion: This study found that the progression-free survival and overall survival are similar between
women treated with chemotherapy on or off trial for cervical cancer.
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Despite advances in the detection and primary treatment of
cervical cancer, an estimated 275,000 women died of this disease in
2010 globally.1 Survival outcome in most women with recurrent
cervical cancer that is not amenable to radical excision or curative
local radiation is usually less than 1 year.2 These patients are
generally candidates for cytotoxic chemotherapy. Cisplatin is the
mainstay of salvage therapy for advanced or recurrent cervicalUniversity of Texas Southwestern Medical Center, Dallas, TX
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Clinical Ovarian and Other Gynecologic Cancer December 2013carcinoma, with a response rate of approximately 20%.3 Several
recent phase III trials conducted by the Gynecologic Oncology
Group (GOG) have combined cisplatin with other chemothera-
peutic agents in an attempt to improve survival.2,4-6 From these
studies, the doublet of cisplatin/paclitaxel has emerged as the
preferred regimen when treatment other than a clinical trial is
considered in women with recurrent cervical cancer.4
Owing to the dismal prognosis of recurrent cervical cancer and
the uncertain effects of treatment interventions, women are
enrolled in clinical trials in an attempt to improve prognosis and
treatment outcomes. Randomized clinical trials are the deﬁnitive
method of comparing the efﬁcacy of treatment regimens and are
critical for improving cancer treatments. Successful treatment
regimens that arise from positive clinical trials are subsequently
applied to clinical practice. A recurring concern about translation2212-9553/$ - see frontmatter ª 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2014.06.004
Table 1 Characteristics of Women With Cervical Cancer
Managed on a Clinical Trial Compared With Matched
Women Managed off Trial
Characteristic
On Clinical
Trial (n [ 30)
Off Clinical
Trial (n [ 30)
Age (years), Mean (Range) 41 (27-67) 44 (25-61)
Race/Ethnicity, n (%)
White 10 (33) 9 (30)
African American 6 (20) 5 (17)
Hispanic 14 (47) 14 (47)
Asian 0 (0) 2 (6)
Body Mass Index, Mean (Range) 25 (17-40) 27.5 (16-69)
Baseline Creatinine, Mean (Range) 0.7 (0.42-1.3) 0.7 (0.5-1.2)
Cervical Cancer Stage, n (%)
IB 11 (37) 11 (37)
IIA 2 (6) 2 (6)
IIB 12 (40) 12 (40)
IIIB 5 (17) 5 (17)
Tumor Grade, n (%)
1 0 (0) 1 (3)
2 13 (43) 11 (37)
3 5 (17) 10 (33)
Unknown 12 (40) 8 (27)
Histology, n (%)
Squamous 25 (83) 25 (83)
Adenocarcinoma 5 (17) 5 (17)of clinical trials to clinical practice is whether similar results can be
reproduced outside the trials. Authors of several studies have
examined these issues of translation of clinical trials to clinical
practice in several disease sites, with some ﬁnding reproducibility
of clinical trial efﬁcacy.7-17
To the present authors’ knowledge, recurrent cervical cancer
has not been studied in the context of clinical trial participation
versus the absence of participation. The generalizability of the
results of trials in cervical cancer is particularly pertinent because
most women have a low-resource, low-socioeconomic background
with inherent barriers to clinical trial participation. The authors
hypothesized that clinical trial participation for patients with
cervical cancer would have a positive trial effect. That is, partic-
ipation in a clinical trial would enhance overall clinical outcomes.
The objective of this study was to compare the clinical outcomes
of patients with recurrent cervical cancer treated on a clinical trial
versus those treated off trial with a similar treatment regimen.
Patients and Methods
This was a retrospective cohort study of patients receiving ﬁrst-line
salvage chemotherapy for recurrent cervical cancer on a clinical trial
versus platinum-based combination chemotherapy not on a trial at
Parkland Memorial Hospital and the University of Texas South-
western Medical Center during the 1998-2010 period. Approval
to conduct this study was obtained from the institutional review
boards at both institutions. All women receiving ﬁrst-line salvage
therapy for recurrent cervical cancer on a GOG trial between 1998
and 2010 were identiﬁed. All trials included cisplatin or a cisplatin
combination regimen as the control arm. Off-trial patients generally
received cisplatin combined with topotecan or paclitaxel. Women
treated on a clinical trial were matched 1:1 to off-trial women using
the following parameters: age within 10 years, ethnicity and race,
stage at initial diagnosis, histology, primary treatment, and baseline
renal function. All women treated for a recurrence had a pretrial
performance status of 0 to 2. Patients treated off trial were potentially
eligible for trial participation but were not enrolled because of
unwillingness to participate or lack of trial availability.
Patients were identiﬁed using tumor registries and institutional
databases at Parkland Memorial Hospital and University Hospital
St Paul (Dallas, TX). Patient and demographic data were
collected retrospectively from each patient’s medical record.
Initial tumor stage was determined clinically at the time of the
patient’s initial examination or an examination under anesthesia.
Date of initial diagnosis, primary treatment, clinical stage, his-
tology, grade, lymph vascular space invasion, and stromal inva-
sion were recorded. Initial treatment information including
surgical management, radiation therapy (routes and doses),
chemotherapeutic agents, and number of cycles was also recor-
ded. Recurrence was deﬁned as the date on which pathologic
evidence of recurrence was obtained. Information including
location of recurrence, treatment of recurrence, date of progres-
sion, subsequent salvage regimens, and date of last follow-up or
death was also recorded.
Statistical Analysis
Overall survival from recurrence was the primary endpoint for
this study. Either the date of last follow-up or the date of thepatient’s death served as the calculation point, and patients were
censored accordingly. Survival was calculated from the time of
recurrence to the date of last follow-up or death. Progression-free
survival was calculated from the time of recurrence to the date of
documented progression. Paired t tests were used to compare
descriptive statistics. Progression-free survival, overall survival, and
survival times from recurrence were calculated and compared using
the Kaplan-Meier method and log-rank test.
Results
The characteristics of 30 women treated for recurrent cervical
cancer and their 30 matched controls are summarized in Table 1.
There was no signiﬁcant difference in demographic characteristics.
Of those 60 patients, 85% (n ¼ 51; 24 on clinical trial and 27 off
clinical trial) received treatment at a county hospital, whereas 15%
(n ¼ 9; 6 on a clinical trial and 3 off clinical trial) were treated in a
private setting (P ¼ .47). Regimens were as follows: 42 women
(70%) were initially treated with cisplatin plus radiation; 8 (13%)
received radiation alone; 6 (10%) underwent radical hysterectomy
with lymphadenectomy followed by chemoradiotherapy; and 4
(7%) underwent radical hysterectomy with lymphadenectomy
without adjuvant treatment.
All 60 women in this analysis received salvage chemotherapy on
GOG trials (n ¼ 30) or off trial (n ¼ 30). All off-trial patients
received ﬁrst-line salvage with either cisplatin/topotecan or cisplatin/
paclitaxel, except 1 patient who received cisplatin/irinotecan. TheClinical Ovarian and Other Gynecologic Cancer December 2013 - 43
Figure 2 Comparison of Progression-Free Survival From
Recurrence in Women Treated on Versus off Clinical
Trial
Table 2 Salvage Regimens Used in Women With Recurrent
Cervical Cancer
No. of Salvage
Regimens
On Clinical Trial
(n [ 30)
Off Clinical Trial
(n [ 30) P
1 16 15 e
2 5 9 e
3 7 4 e
4 0 1 e
5 2 1 e
Median 1.0 1.5 .74
Survival Outcomes in Recurrent Cervical Cancer
44 -numbers of salvage regimens received are shown in Table 2. The
median number of salvage regimens was 1.0 for the trial group
(range, 1-5) and 1.5 for the off-trial group (range, 1-5) (P ¼ .74).
There was also no signiﬁcant difference in the median number of
total salvage cycles of chemotherapy completed by on-trial versus
off-trial groups (6 vs. 3; P ¼ .44). As shown in Figure 1, the most
common site for single-site recurrence was the pelvis.
As shown in Figure 2, there was no difference in progression-free
survival from the time of recurrence between the 2 study groups (on
trial, 4.2 months; off trial, 3.1 months; P ¼ .75). Overall survival
time from recurrence (Figure 3) also did not differ between patients
treated on versus off clinical trial (15.0 vs. 13.8 months; P ¼ .64).
When patients were stratiﬁed by early-stage versus late-stage cervical
cancer at initial diagnosis, there was also no signiﬁcant difference in
survival from the time of recurrence (data not shown).
Discussion
The present ﬁndings indicate that results from clinical trials can
be translated (ie, are generalizable) to women with recurrent cervical
cancer who are not on a clinical trial. One consequence of this is
that clinicians can have more conﬁdence that treatment guidelines
based on randomized clinical trials are relevant to routine clinical
practice.
Recruitment and enrollment in clinical trials is inﬂuenced by the
physician’s initiative as well as the patient’s willingness toFigure 1 Location of Recurrences in Women With Cervical
Cancer
Clinical Ovarian and Other Gynecologic Cancer December 2013participate. Other factors affecting enrollment in clinical cancer
trials include perceptions of the patient’s potential compliance,
absence of certain comorbidities, and access to care. Importantly,
women not qualifying or unwilling to participate are treated with
standard-of-care therapy, which in most cases corresponds to 1
randomization arm of the clinical trial. Such women likely are
intrinsically at higher risk for clinical trial screening failure, hence
enhancing the efﬁciency of clinical trials.
The present authors are of the view that such dynamics were
mitigated somewhat by this study’s design. That is, the control
group was selected based on intrinsic recurrent cervical cancer fea-
tures and morbidities and not based on extrinsic health care access
and other social dynamics. Said another way, careful matching of
women with recurrent cervical cancer minimized the distortion of
management results and cancer outcomes inevitable when the pa-
tient or provider controls the enrollment.
This study is a retrospective study of women treated for
recurrent cervical cancer and therefore carries the limitations
inherent to this type of review. The small study size was limited
by the number of women enrolled on GOG trials during theFigure 3 Comparison of Overall Survival From Recurrence in
Women Treated on Versus off Clinical Trial
Christa I. Nagel et alstudy time period. Although the study had a limited sample size,
the authors believe that an advantage of the study is that it
represents a single institution’s experience and includes a large
minority population. Future studies involving prospective multi-
institutional involvement will be necessary to further evaluate the
generalizability of clinical trial results in a broader population
with cervical cancer.
Conclusion
The present results suggest the lack of a clinical trial effect in
this study’s patient population, highlighting that the information
gained from these trials is applicable to similar patients outside of
a trial. Women should continue to be encouraged to enroll in
clinical trials regardless of potential extrinsic social barriers, because
trials with valid design and selection are critical for the discovery of
novel agents that will improve survival for women with cervical
cancer.
Clinical Practice Points
 A large proportion of cervical cancer patients have a lower
socioeconomic background with inherent barriers to clinical trial
participation. To our knowledge, there have been no studies to
date that have speciﬁcally looked at outcomes of patients with
cervical cancer treated on versus off of a clinical trial.
 Our results suggest in our patient population the lack of a clinical
trial effect, highlighting that the information gained from these
trials is applicable to similar patients outside of a trial.
 Women should continue to be encouraged to enroll in clinical
trials regardless of potential extrinsic social barriers; as such trials
are critical for the discovery of novel agents that will improve
survival for cervical cancer.
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